Condition: Histiocytic Neoplasms · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
This description comes directly from the study's public registry record.
Eli Diamond, MD · 212-610-0243 · diamone1@mskcc.org
Rona Yaeger, MD · 646-888-5109
Always discuss trial participation with your own doctor first.
| Mayo Clinic (Data Collection Only) | Rochester, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Basking Ridge (Consent Only) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Consent Only) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (Consent Only) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Consent Only) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06411821